199 related articles for article (PubMed ID: 16409469)
41. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.
van 't Veer C; Golden NJ; Mann KG
Blood; 2000 Feb; 95(4):1330-5. PubMed ID: 10666207
[TBL] [Abstract][Full Text] [Related]
42. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor.
Livnat T; Martinowitz U; Zivelin A; Rima D; Kenet G
Thromb Haemost; 2011 Apr; 105(4):688-95. PubMed ID: 21225093
[TBL] [Abstract][Full Text] [Related]
43. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
Doshi BS; Gangadharan B; Doering CB; Meeks SL
PLoS One; 2012; 7(10):e48172. PubMed ID: 23144741
[TBL] [Abstract][Full Text] [Related]
44. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation.
Hoffman M; Monroe DM; Oliver JA; Roberts HR
Blood; 1995 Sep; 86(5):1794-801. PubMed ID: 7655009
[TBL] [Abstract][Full Text] [Related]
45. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
Gerotziafas GT; Depasse F; Chakroun T; Samama MM; Elalamy I
Thromb Haemost; 2004 Mar; 91(3):531-7. PubMed ID: 14983229
[TBL] [Abstract][Full Text] [Related]
46. Recombinant factor VIIa: its background, development and clinical use.
Hedner U
Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
[TBL] [Abstract][Full Text] [Related]
47. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
Allen GA; Persson E; Campbell RA; Ezban M; Hedner U; Wolberg AS
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):683-9. PubMed ID: 17204663
[TBL] [Abstract][Full Text] [Related]
48. Activation of bovine factor IX by the reaction product of bovine factor VII and human tissue factor.
Liu DY; Rosen S
Chin Med J (Engl); 1994 Mar; 107(3):181-5. PubMed ID: 8088177
[TBL] [Abstract][Full Text] [Related]
49. Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent.
Hedner U; Brun NC
Neuroradiology; 2007 Oct; 49(10):789-93. PubMed ID: 17653706
[TBL] [Abstract][Full Text] [Related]
50. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Allen GA; Hoffman M; Roberts HR; Monroe DM
Can J Anaesth; 2002 Dec; 49(10):S7-14. PubMed ID: 12546000
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.
Keshava S; Pendurthi UR; Esmon CT; Rao LVM
J Thromb Haemost; 2020 Aug; 18(8):1911-1921. PubMed ID: 32359012
[TBL] [Abstract][Full Text] [Related]
52. NovoSeven: mode of action and use in acquired haemophilia.
Von Depka M
Intensive Care Med; 2002 Oct; 28 Suppl 2():S222-7. PubMed ID: 12404090
[TBL] [Abstract][Full Text] [Related]
53. A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation.
Wan J; Tanratana P; Roest M; Gruber A; Pawlinski R; Wolberg AS; Mackman N; Grover SP
Blood Adv; 2023 May; 7(9):1915-1925. PubMed ID: 36583671
[TBL] [Abstract][Full Text] [Related]
54. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
[TBL] [Abstract][Full Text] [Related]
55. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.
Yada K; Fujitate N; Ogiwara K; Soeda T; Kitazawa T; Nogami K
Thromb Res; 2024 May; 237():37-45. PubMed ID: 38547693
[TBL] [Abstract][Full Text] [Related]
56. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis.
Shima M
Semin Hematol; 2004 Jan; 41(1 Suppl 1):125-31. PubMed ID: 14872433
[TBL] [Abstract][Full Text] [Related]
57. Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
Weeterings C; Lisman T; de Groot PG
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S12-5. PubMed ID: 18544417
[TBL] [Abstract][Full Text] [Related]
58. In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
Augustsson C; Persson E
Blood; 2014 Nov; 124(20):3172-4. PubMed ID: 25232061
[TBL] [Abstract][Full Text] [Related]
59. A possible mechanism of action of activated factor VII independent of tissue factor.
Monroe DM; Hoffman M; Oliver JA; Roberts HR
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S15-20. PubMed ID: 9819024
[TBL] [Abstract][Full Text] [Related]
60. Recombinant factor VIIa (NovoSeven) as a hemostatic agent.
Hedner U
Dis Mon; 2003 Jan; 49(1):39-48. PubMed ID: 12525827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
